Nova Mentis Life Science Corp (CSE: NOVA) (FSE: HN3Q) (OTCPK: NMLSF)

The Nova Mission

We’re a Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Our mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome.

Nova is the first company to achieve psilocybin orphan drug
designation in both the U.S. and European Union for the treatment of
fragile X syndrome, the leading genetic cause of symptoms
related to autism spectrum disorder.

This provides us with financial benefits, market exclusivity,
research assistance and access to grants.

Autism Spectrum Disorder and Fragile X Syndrome Observational Study

Learn More

Latest News

Nov 30, 2022

Nova Submits Phase II A Psilocybin Clinical Trial Application to Health Canada

Microdose Psilocybin Safety and Efficacy Clinical Study in Fragile X Syndrome

Vancouver, British Columbia – November 30, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders ...

Nov 17, 2022

Nova Mentis Enters into Research Contract with KGK Science for Phase II A Clinical Trial

Vancouver, British Columbia – November 17, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (OTCQB: NMLSF) (FSE: HN3Q) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has entered into a research services agreement with KGK Sciences Inc. (KGK), a wholly owned subsidiary of Wellness Digital Science Inc. (NEO: MEDI) (OTC: KONEF)